Biovica receives patent approval in Japan

Biovica International AB (publ) have received a new patent in Japan. The patent refers to Biovica’s method of measuring thymidine kinase activity on a real-time PCR platform. The new patent is valid until 13th of May 2031. With this patent, Biovica has received patent protection for the PCR-based product on all 16 markets the company has applied for patent protection.

”It is important for Biovica to protect our unique technology. Hence, it is positive news that we get improved patent protection on one of the more important markets. Patent protection is important in order to be able to bring our products to the market to contribute to best possible treatment for cancer patients.”, says Anders Rylander, CEO Biovica.


More information:

Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,

This information is information that Biovica International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person(s) set out above, at 11.00 CET on August 23, 2018.

In the event of contradictions or differences between the Swedish press release and this English version the Swedish text will prevail.

About Biovica

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.

Read more:

2020-02-19T13:39:43+00:00 August 23rd, 2018 11:00|Regulatory|